ESMO 2022 Conference Coverage


 

ESMO 2022 Final Analysis of the Randomized, Phase 3 RATIONALE-301 Study: Tislelizumab vs. Sorafenib as 1L Treatment for Unresectable HCC

104 views
September 19, 2022
Comments 0
Login to view comments. Click here to Login